At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes
In Brief
A Early Phase 1 clinical trial evaluating ePID closed loop system and liraglutide for Type 1 Diabetes. Completed, enrolled 15 participants across 1 site.
Detailed Summary
"Closed loop artificial pancreas" systems have been under development for the control of blood sugars in those living with diabetes. These systems consist of a continuous glucose sensor, which sends a signal to a computer program that automatically determines how much insulin to give. The computer program then tells an insulin pump to deliver the insulin. While such systems have been tested under a number of conditions, post-meal blood sugars are difficult to control. This study is designed to see if liraglutide, a glucagon like peptide receptor agonist, can help minimize the post meal blood sugar spikes in subjects with type 1 diabetes while they are on a closed loop system.
Study Details
Timeline
Interventions
Insulin pump controlled by closed loop unit and algorithm
Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist